News Articles

Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses CAMBRIDGE, Mass. & OSAKA, Japan -Monday 20 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology...

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority... -Monday 20 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha...

Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health" -Saturday 18 May 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in...

Takeda Reports FY2018 Full Year Results and Issues FY2019 Guidance -Thursday 16 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): FY2018 Full Year Results Legacy Takeda Underlying Revenue +5.3%; Consolidated reported revenue +18.5% Underlying Revenue growth for Legacy Takeda was solid at +5.3%, with significant contributions from...

Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress... -Wednesday 15 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 7 presentations, including one oral presentation, at the upcoming European Congress of Endocrinology (ECE) Annual Meeting from May 18-21, 2019 in Lyon, France. The data...

U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation... -Thursday 9 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a subcutaneous (SC) formulation of vedolizumab for maintenance therapy in...

Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures -Thursday 9 May 2019

Agrees to Sell Xiidra® to Novartis for up to $5.3 billion Company to Also Divest TachoSil® to Ethicon* for approximately $400 million   (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to...

Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International... -Wednesday 8 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the 15th International Symposium on Myelodysplastic Syndromes taking place in...

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term... -Tuesday 26 March 2019

Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into continuous use of rhPTH(1-84) shows improvements in key measurements of mineral homeostasis   (BUSINESS WIRE)-- Takeda Pharmaceutical Company...

Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever... -Saturday 9 March 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha...

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults... -Tuesday 12 February 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS (brentuximab vedotin) to include treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin...

Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis... -Thursday 7 February 2019

The PROPEL study compared the safety and efficacy of ADYNOVATE® [Antihemophilic Factor [Recombinant], PEGylated] following pharmacokinetic (PK)-guided prophylaxis, targeting two different factor VIII trough levels The novel design of the study was built upon preliminary data indicating...

Takeda Reports Third Quarter FY2018 Results -Monday 4 February 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue +4.8% year-to-date with growth of prescription drug portfolio in all regions Solid Underlying Revenue growth of +4.8%, with continued strong momentum from Takeda's Growth Drivers...

Takeda Scoops Prestigious Global Top Employers® Award for Second Year Running -Friday 1 February 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited [TOKYO: 4502 / NYSE: TAK], (“Takeda”) today announced it has become part of a select group of only 12 to receive global Top Employer® status for 2019. Established over 25 years ago, award certification is given annually by the Top...

Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial -Friday 1 February 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited [TSE:4502 / NYSE:TAK] (“Takeda”) today announced that the pivotal Phase 3 trial of its dengue vaccine candidate met the primary efficacy endpoint. This first analysis of the Tetravalent Immunization against Dengue Efficacy Study...

Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader -Wednesday 9 January 2019

8 months from deal announcement to deal close Strong shareholder support with high approval rates on Takeda (89.1%) and Shire (99.8%) Integration planning well underway (BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced the...

Takeda Notes Court Sanction of the Scheme of Arrangement with Respect to the Acquisition of Shire plc -Friday 4 January 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) notes Shire plc’s (“Shire”) announcement that the Royal Court of Jersey (the “Jersey Court”) has today sanctioned the scheme of arrangement (the “Scheme”) pursuant to which the proposed...

Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio -Friday 4 January 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company. Through these collaborations, Takeda seeks to accelerate the discovery of next-generation...

Takeda Announces Listing of American Depositary Shares on the New York Stock Exchange -Thursday 20 December 2018

(BUSINESS WIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today...

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult... -Monday 17 December 2018

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin)...